Alexion Pharmaceuticals Inc (ALXN)

182.50 0.00 (0.00%)
Closed USD Disclaimer

Alexion Pharmaceuticals Inc Company Profile

Industry
-
Sector
-
Employees
3837
Equity Type
ORD
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. It offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma sebelipase alfa for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 Intravenous, which is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 Subcutaneous, which is in Phase III clinical trials for PNH and aHUS; ALXN1820, which is in Phase I clinical trial as a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840, which is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which is in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for the treatment of relapsed/refractory chronic lymphocytic leukemia. It serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has a collaboration and license agreement with Neurimmune AG, Dicerna, Merck, and Zealand Pharma. The company was incorporated in 1992 and is based in Boston, Massachusetts, with an additional office in Baar, Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Contact Information
Address
Boston,02210 United States
Phone
(475) 230 2596
Fax
(203) 271 8198

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.